Navigation Links
VNUS Medical's Patent Lawsuit Against Laser Competitors to Proceed to Trial
Date:10/3/2007

SAN JOSE, Calif., Oct. 3 /PRNewswire-FirstCall/ -- The patent lawsuit by VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS) against three endovenous laser competitors, Diomed, AngioDynamics and Vascular Solutions, is set to proceed to trial after the court's denial of summary judgment motions filed by both sides. In its motions VNUS had asked the court to decide before trial that the three defendants infringed the VNUS patents, while the defendants countered with their own motions seeking pre-trial rulings that the VNUS patents were invalid. The court denied all but one of the motions, deferring for later decision one of the defendants' patent invalidity motions. The court asked VNUS for an additional brief on the deferred invalidity motion because the defendants had raised a new argument in their most recent brief on the issue, and the court sought a response from VNUS before deciding. According to an order issued on Oct. 3, a decision is expected from the court sometime after VNUS submits its additional brief on Oct. 12.

VNUS CEO Brian Farley commented: "Although both sides would have been pleased to have the court grant their respective pre-trial motions, we look forward to putting forth our case in a full trial. We feel strongly that the more the court hears about the success of our technology and the impact it has had on patients' lives, the more compelling our case becomes."

ABOUT VNUS MEDICAL TECHNOLOGIES, INC.

Founded in 1995 and headquartered in San Jose, California, VNUS Medical Technologies (Nasdaq: VNUS) is a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition that causes the varicose veins afflicting 25 million Americans. The pioneering company in the field, VNUS now offers the ClosureFAST(R) system, which consists of a proprietary radiofrequency (RF) generator and proprietary disposable endovenous catheters and devices to close diseased veins through the application of temperature-controlled RF energy. VNUS devices have been used in more than 200,000 procedures worldwide. For more information, please visit http://www.vnus.com .

FORWARD-LOOKING STATEMENTS

In addition to statements of historical facts or statements of current conditions, VNUS has made forward-looking statements in this press release. Words such as "thinks," "believes," "feels" or variations of such words and similar expressions, are intended to identify such forward-looking statements in this press release. Actual results may differ materially from current expectations based on a number of factors affecting the conduct of the patent lawsuit discussed herein, including, among other things, ambiguity and unforeseen changes in the relevant law, the composition and behavior of a jury, the degree of credibility with which witnesses testify, and the inherent unpredictability of civil litigation and civil trials. The reader is cautioned not to unduly rely on these forward-looking statements. VNUS expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Additional information concerning these and other risk factors can be found in press releases issued by VNUS and VNUS' periodic public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K filed with the SEC on March 30, 2007. Copies of VNUS' press releases and additional information about VNUS are available on the corporate website at http://www.vnus.com .


'/>"/>
SOURCE VNUS Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Hospitals Appeal to Citizen Groups to Rush Doctors, Paramedicals
2. Indian Doctor granted US patent on organ regeneration
3. Dr Reddy’s Laboratories to challenge patents on drug
4. Yoga, ayurveda being documented to stop patent misuse
5. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
6. US Court Rules Against Lupin in Ramipril Patent Case
7. HIV Patients Opposes Patenting Of AIDS Drug
8. Provigil Patent Extension Accorded To Cephalon
9. AIDS Sufferers Protest against Proposed Patent for Tenofovir
10. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
11. Venus Remedies Files 5th International Patent Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... ... at his Inauguration that WesternU will move forward in bold new directions while ... WesternU combined Wilson’s Inauguration ceremony with Convocation, the traditional opening of the academic ...
(Date:8/15/2017)... ... August 15, 2017 , ... Horizon Goodwill is honored to ... are overwhelmed with gratitude for the very generous donation from BB&T. Our mission ... both get a job and keep it. This donation will go a long ...
(Date:8/15/2017)... ... August 15, 2017 , ... IsoComforter, Inc., one of the ... innovative new 10x10 bladder pad ( isocomforter.com/product/10x10-sterile-pad/ ). The newly designed bladder pad ... enables the patient to enjoy the benefits of cold therapy while resting, sitting, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Harris Communications, Inc. is bringing its ... Twin Cities Living Well with Hearing Loss Conference, 9:30-2 p.m. Saturday, Nov. 18 at ... for Harris Communications at tables 8 and 9. , During the conference, attendees can ...
(Date:8/15/2017)... Glan Allen,VA (PRWEB) , ... August 15, 2017 ... ... of CoolSculpting to their leading selection of services. FDA-cleared CoolSculpting is the world’s ... and counting. Without surgery or downtime, CoolSculpting can reduce fat cells in almost ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
(Date:7/25/2017)... -- Debbie,s Dream Foundation: Curing Stomach Cancer (DDF) is excited to host its 3 ... Bonaventure Resort & Spa in Weston, Florida beginning at ... Luncheon Committee Co-chair ... Luncheon Committee Co-chair Sabrina Kurzman. ... Aura Morales-Guzman, Angela Perez, DDF Board Member John ...
Breaking Medicine Technology: